99mTc-HDP bone scintigraphy and 18F-sodiumfluoride PET/CT in primary staging of patients with prostate cancer - Takeaways - MDSpire

99mTc-HDP bone scintigraphy and 18F-sodiumfluoride PET/CT in primary staging of patients with prostate cancer

  • By

  • Maurits Wondergem

  • Friso M. van der Zant

  • Remco J. J. Knol

  • Anne Marij G. Burgers

  • Siebe D. Bos

  • Igle J. de Jong

  • Jan Pruim

  • October 17, 2017

  • 0 min

Share

  • 1

    Prostate cancer is the most common cancer in men, with significant mortality rates, necessitating early detection of skeletal metastases.

  • 2

    99mTc-HDP bone scintigraphy has been the standard for detecting bone metastases, but its guidelines are based on outdated studies.

  • 3

    18F-sodiumfluoride PET/CT has shown superior performance compared to 99mTc-HDP in detecting bone metastases, though data is limited.

  • 4

    The study compares diagnostic performance and clinical impact of NaF PET/CT and BS in patients with prostate cancer.

  • 5

    Both imaging modalities were evaluated for sensitivity, specificity, and management impact, with NaF PET/CT introduced in clinical practice in 2014.

Original Source(s)

99mTc-HDP bone scintigraphy and 18F-sodiumfluoride PET/CT in primary staging of patients with prostate cancer

  • by Maurits Wondergem, Friso M. van der Zant, Remco J. J. Knol, Anne Marij G. Burgers, Siebe D. Bos, Igle J. de Jong, Jan Pruim

  • October 17, 2017

Related Content

Combined T2 and diffusion-weighted MR imaging with template prostate biopsies in men suspected with prostate cancer but negative transrectal ultrasound-guided biopsies

Combining prostate health index and multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer in an Asian population

Poor reproducibility of PIRADS score in two multiparametric MRIs before biopsy in men with elevated PSA